Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N. Parma G, et al. Among authors: hess d. Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a. Int J Gynecol Cancer. 2012. PMID: 22635029 Clinical Trial.
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O, Sessa C, Nolè F, Crivellari D, Lombardi D, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A. Pagani O, et al. Among authors: d incalci m, hess d. Ann Oncol. 2000 Aug;11(8):985-91. doi: 10.1023/a:1008392927656. Ann Oncol. 2000. PMID: 11038035 Free article. Clinical Trial.
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A; International Breast Cancer Study Group. Crivellari D, et al. Among authors: hess d. Ann Oncol. 2001 Mar;12(3):353-6. doi: 10.1023/a:1011132609055. Ann Oncol. 2001. PMID: 11332148 Free article. Clinical Trial.
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L. Sessa C, et al. Among authors: d incalci m, hess d. Ann Oncol. 2007 Mar;18(3):561-8. doi: 10.1093/annonc/mdl418. Epub 2006 Dec 5. Ann Oncol. 2007. PMID: 17150998 Free article. Clinical Trial.
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L. Perotti A, et al. Among authors: hess d. J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855840 Clinical Trial.
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. Gallerani E, et al. Among authors: d incalci m, hess d. Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Eur J Cancer. 2013. PMID: 23058787 Review.
1,612 results